Resistant Chronic Myeloid Leukemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for resistant chronic myeloid leukemia. 1 active patents protecting 1 drugs from 0+ originators. First major cliff: 2041. Daily refresh.

1
Approved drugs
1
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Resistant Chronic Myeloid Leukemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating resistant chronic myeloid leukemia. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
HYDROXYUREA — 1 55 — 2041-12-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12409156 HYDROXYUREA formulation 55 2041-12-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12409156 HYDROXYUREA formulation 55 2041-12-23

Related